Payment overview · 2025
General Payments
$593.01
33 reported records · 15 companies
Healthcare provider profile · identity verified
Robert Allen Martin, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST PLAINS, MO · NPI 1841297181
Verified facts
What the public records show
CMS Open Payments records show Robert Allen Martin, MD received $593.01 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.53 | 13.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.66 | 12.2% | 4 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $68.13 | 11.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.31 | 10.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.49 | 8.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.35 | 8.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.65 | 8.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.53 | 5.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.79 | 5.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.70 | 3.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.37 | 3.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $15.45 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.93 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.10 | 2.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.02 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $593.01 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.66 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $69.72 | 4 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $68.13 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $61.31 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.49 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| JADA SYSTEM Normalized: jada system |
Device | Organon LLC | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 552 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 492 | 94 |
| Furosemide | Furosemide | 431 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 428 | 85 |
| Gabapentin | Gabapentin | 404 | 73 |
| Tramadol Hcl | Tramadol Hcl | 395 | 82 |
| Lisinopril | Lisinopril | 328 | 64 |
| Potassium Chloride | Potassium Chloride | 322 | 70 |
| Omeprazole | Omeprazole | 303 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 45 |
| Prednisone | Prednisone | 242 | 69 |
| Trazodone Hcl | Trazodone Hcl | 236 | 52 |
| Eliquis | Apixaban | 230 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 196 | 38 |
| Losartan Potassium | Losartan Potassium | 187 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 31 |
| Montelukast Sodium | Montelukast Sodium | 170 | 41 |
| Simvastatin | Simvastatin | 168 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 40 |
| Metformin Hcl | Metformin Hcl | 150 | 36 |
| Sertraline Hcl | Sertraline Hcl | 147 | 19 |
| Pregabalin | Pregabalin | 145 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 143 | 22 |
| Risperidone | Risperidone | 133 | suppressed |
| Spironolactone | Spironolactone | 128 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 37 |
| Carvedilol | Carvedilol | 112 | 14 |
| Ozempic | Semaglutide | 109 | 18 |
| Lorazepam | Lorazepam | 103 | 27 |
| Metformin Hcl Er | Metformin Hcl | 100 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 23 |
| Finasteride | Finasteride | 98 | 22 |
| Clonazepam | Clonazepam | 92 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 20 |
| Donepezil Hcl | Donepezil Hcl | 89 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 15 |
| Bupropion Xl | Bupropion Hcl | 84 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 17 |
| Famotidine | Famotidine | 77 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 13 |
| Diazepam | Diazepam | 75 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 21 |
| Memantine Hcl | Memantine Hcl | 73 | 11 |
| Meloxicam | Meloxicam | 70 | 21 |
| Metolazone | Metolazone | 68 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 12 |
| Farxiga | Dapagliflozin Propanediol | 65 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 16 |
| Alendronate Sodium | Alendronate Sodium | 62 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 15 |
| Methotrexate | Methotrexate Sodium | 61 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 60 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 14 |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Mirtazapine | Mirtazapine | 57 | 12 |
| Allopurinol | Allopurinol | 56 | 14 |
| Fluconazole | Fluconazole | 55 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 52 | 16 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Ibuprofen | Ibuprofen | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 20 |
| Nystatin | Nystatin | 44 | 27 |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 27 |
| Ondansetron Odt | Ondansetron | 43 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 31 |
| Azithromycin | Azithromycin | 39 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Rexulti | Brexpiprazole | 38 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 24 |
| Cefuroxime | Cefuroxime Axetil | 35 | 29 |
| Digoxin | Digoxin | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 19 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Erythromycin | Erythromycin Base | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Xtampza Er | Oxycodone Myristate | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Fentanyl | Fentanyl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 20 | 14 |
| Cefdinir | Cefdinir | 20 | 18 |
| Atenolol | Atenolol | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Itraconazole | Itraconazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $593.01 · 33 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, ENTRESTO, FREESTYLE LIBRE, GARDASIL 9, JADA SYSTEM, LEQVIO, MONOFERRIC, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, Rybelsus, VAXNEUVANCE, Wegovy, YUPELRI | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error